<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36533811</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>Identification of potential pathways and biomarkers linked to progression in ALS.</ArticleTitle><Pagination><StartPage>150</StartPage><EndPage>165</EndPage><MedlinePgn>150-165</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.51697</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To identify potential diagnostic and prognostic biomarkers for clinical management and clinical trials in amyotrophic lateral sclerosis.</AbstractText><AbstractText Label="METHODS">We analysed proteomics data of ALS patient-induced pluripotent stem cell-derived motor neurons available through the AnswerALS consortium. After stratifying patients using clinical ALSFRS-R and ALS-CBS scales, we identified differentially expressed proteins indicative of ALS disease severity and progression rate as candidate ALS-related and prognostic biomarkers. Pathway analysis for identified proteins was performed using STITCH. Protein sets were correlated with the effects of drugs using the Connectivity Map tool to identify compounds likely to affect similar pathways. RNAi screening was performed in a Drosophila TDP-43 ALS model to validate pathological relevance. A statistical classification machine learning model was constructed using ridge regression that uses proteomics data to differentiate ALS patients from controls.</AbstractText><AbstractText Label="RESULTS">We identified 76, 21, 71 and 1 candidate ALS-related biomarkers and 22, 41, 27 and 64 candidate prognostic biomarkers from patients stratified by ALSFRS-R baseline, ALSFRS-R progression slope, ALS-CBS baseline and ALS-CBS progression slope, respectively. Nineteen proteins enhanced or suppressed pathogenic eye phenotypes in the ALS fly model. Nutraceuticals, dopamine pathway modulators, statins, anti-inflammatories and antimicrobials were predicted starting points for drug repurposing using the connectivity map tool. Ten diagnostic biomarker proteins were predicted by machine learning to identify ALS patients with high accuracy and sensitivity.</AbstractText><AbstractText Label="INTERPRETATION">This study showcases the powerful approach of iPSC-motor neuron proteomics combined with machine learning and biological confirmation in the prediction of novel mechanisms and diagnostic and predictive biomarkers in ALS.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huber</LastName><ForeName>Roland G</ForeName><Initials>RG</Initials><Identifier Source="ORCID">0000-0001-5093-5988</Identifier><AffiliationInfo><Affiliation>Bioinformatics Institute (BII), Agency for Science, Technology and Research (A*STAR), Matrix #07-01, 30 Biopolis Street, Singapore, 138671, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pandey</LastName><ForeName>Swapnil</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5086-709X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, McKnight Brain Institute, and Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, Florida, 32611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhangani</LastName><ForeName>Deepak</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-3971-7589</Identifier><AffiliationInfo><Affiliation>Department of Neurology, McKnight Brain Institute, and Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, Florida, 32611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rincon-Limas</LastName><ForeName>Diego E</ForeName><Initials>DE</Initials><Identifier Source="ORCID">0000-0003-3099-0642</Identifier><AffiliationInfo><Affiliation>Department of Neurology, McKnight Brain Institute, and Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, Florida, 32611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staff</LastName><ForeName>Nathan P</ForeName><Initials>NP</Initials><Identifier Source="ORCID">0000-0001-6760-3859</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota, 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeo</LastName><ForeName>Crystal Jing Jing</ForeName><Initials>CJJ</Initials><Identifier Source="ORCID">0000-0001-5445-5965</Identifier><AffiliationInfo><Affiliation>Agency for Science, Technology and Research (A*STAR), IMCB, 61 Biopolis Drive, Proteos, Singapore, 138673, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, 60611, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lee Kong Chian School of Medicine, Imperial College London and NTU Singapore, Singapore, 308232, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, AB243FX, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Neuroscience Institute, TTSH Campus, 11 Jalan Tan Tock Seng, Singapore, 308433, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Duke NUS Medical School, 8 College Road, Singapore, 169857, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG059871</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG059871</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="N">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="Y">Proteomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors would like to declare that no potential conflicts of interest with any commercial entities relating to this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>19</Day><Hour>7</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36533811</ArticleId><ArticleId IdType="pmc">PMC9930436</ArticleId><ArticleId IdType="doi">10.1002/acn3.51697</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Xu L, Liu T, Liu L, et&#xa0;al. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta&#x2010;analysis. J Neurol. 2020;267(4):944&#x2010;953.</Citation><ArticleIdList><ArticleId IdType="pubmed">31797084</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H&#x2010;J, Debray TPA, Visser AE, et&#xa0;al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17(5):423&#x2010;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Raaphorst J, Beeldman E, De Visser M, et&#xa0;al. A systematic review of behavioural changes in motor neuron disease. Amyotroph Lateral Scler. 2012;13(6):493&#x2010;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">22424127</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539(7628):197&#x2010;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, Kim H&#x2010;J, Hart MP, et&#xa0;al. Ataxin&#x2010;2 intermediate&#x2010;length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466(7310):1069&#x2010;1075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Muyderman H, Chen T. Mitochondrial dysfunction in amyotrophic lateral sclerosis&#x2013;a valid pharmacological target? Br J Pharmacol. 2014;171(8):2191&#x2010;2205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3976630</ArticleId><ArticleId IdType="pubmed">24148000</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollari E, Goldsteins G, Bart G, et&#xa0;al. The role of oxidative stress in degeneration of the neuromuscular junction in amyotrophic lateral sclerosis. Front Cell Neurosci. 2014;8:131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4026683</ArticleId><ArticleId IdType="pubmed">24860432</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon MS, Wosiski&#x2010;Kuhn M, Gillespie R, Caress J, Milligan C. Inflammation, immunity, and amyotrophic lateral sclerosis: I. Etiology and Pathology. Muscle Nerve. 2019;59(1):10&#x2010;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">29979464</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal NA, Berry JD, Windebank A, et&#xa0;al. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle Nerve. 2020;62(2):156&#x2010;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7496557</ArticleId><ArticleId IdType="pubmed">31899540</ArticleId></ArticleIdList></Reference><Reference><Citation>Saitoh Y, Takahashi Y. Riluzole for the treatment of amyotrophic lateral sclerosis. Neurodegener Dis Manag. 2020;10(6):343&#x2010;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">32847483</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Aoki M, Tsuji S, et&#xa0;al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double&#x2010;blind, placebo&#x2010;controlled trial. Lancet Neurol. 2017;16(7):505&#x2010;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Itoyama Y, Sobue G, et&#xa0;al. Confirmatory double&#x2010;blind, parallel&#x2010;group, placebo&#x2010;controlled study of efficacy and safety of edaravone (MCI&#x2010;186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Front Degener. 2014;15(7&#x2013;8):610&#x2010;617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>Group E (MCI&#x2010;186) ALS 16 S . A post&#x2010;hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI&#x2010;186) in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2017;18(Supp 1):11&#x2010;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">28872917</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxi EG, Thompson T, Li J, et&#xa0;al. Answer ALS, a large&#x2010;scale resource for sporadic and familial ALS combining clinical and multi&#x2010;omics data from induced pluripotent cell lines. Nat Neurosci. 2022;25(2):226&#x2010;237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8825283</ArticleId><ArticleId IdType="pubmed">35115730</ArticleId></ArticleIdList></Reference><Reference><Citation>Smyth GK. limma: linear models for microarray data. In: Gentleman R, Carey VJ, Huber W, Irizarry RA, Dudoit S, eds. Bioinformatics and computational biology solutions using R and bioconductor. Statistics for biology and health. Springer; 2005:397&#x2010;420.</Citation></Reference><Reference><Citation>Gentleman RC, Carey VJ, Bates DM, et&#xa0;al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):1&#x2010;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC545600</ArticleId><ArticleId IdType="pubmed">15461798</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team . R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2013.</Citation></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et&#xa0;al. The ALSFRS&#x2010;R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169(1&#x2013;2):13&#x2010;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolley SC, York MK, Moore DH, et&#xa0;al. Detecting frontotemporal dysfunction in ALS: utility of the ALS cognitive behavioral screen (ALS&#x2010;CBS&#x2122;). Amyotroph Lateral Scler. 2010;11(3):303&#x2010;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">20433413</ArticleId></ArticleIdList></Reference><Reference><Citation>Labra J, Menon P, Byth K, et&#xa0;al. Rate of disease progression: a prognostic biomarker in ALS. J. Neurol. Neurosurg. Psychiatry. 2016;87(6):628&#x2010;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">26152368</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez&#x2010;Gracia JL, G&#xfa;rpide A, Ruiz&#x2010;Ilundain MG, et&#xa0;al. Selection of extreme phenotypes: the role of clinical observation in translational research. Clin Transl Oncol off Publ Fed Spanish Oncol Soc Natl Cancer Inst Mex. 2010;12(3):174&#x2010;180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997959</ArticleId><ArticleId IdType="pubmed">20231122</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinney W. Pandas: a foundational python library for data analysis and statistics. Python High Perform Sci Comput. 2011;14(9):1&#x2010;9.</Citation></Reference><Reference><Citation>Virtanen P, Gommers R, Oliphant TE, et&#xa0;al. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat Methods. 2020;17(3):261&#x2010;272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7056644</ArticleId><ArticleId IdType="pubmed">32015543</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter JD. Matplotlib: a 2D graphics environment. Comput Sci Eng. 2007;9(3):90&#x2010;95.</Citation></Reference><Reference><Citation>Kuhn M, von Mering C, Campillos M, et&#xa0;al. STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res. 2007;36(suppl_1):D684&#x2010;D688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2238848</ArticleId><ArticleId IdType="pubmed">18084021</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn M, Szklarczyk D, Pletscher&#x2010;Frankild S, et&#xa0;al. STITCH 4: integration of protein&#x2013;chemical interactions with user data. Nucleic Acids Res. 2014;42(D1):D401&#x2010;D407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964996</ArticleId><ArticleId IdType="pubmed">24293645</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoerl AE, Kennard RW. Ridge regression: biased estimation for nonorthogonal problems. Dent Tech. 1970;12(1):55&#x2010;67.</Citation></Reference><Reference><Citation>Pedregosa F, Varoquaux G, Gramfort A, et&#xa0;al. Scikit&#x2010;learn: machine learning in python. J Mach Learn Res. 2011;12:2825&#x2010;2830.</Citation></Reference><Reference><Citation>Ritson GP, Custer SK, Freibaum BD, et&#xa0;al. TDP&#x2010;43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. J Neurosci. 2010;30(22):7729&#x2010;7739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890254</ArticleId><ArticleId IdType="pubmed">20519548</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh MD, Jensen M, Lasser M, et&#xa0;al. NCBP2 modulates neurodevelopmental defects of the 3q29 deletion in Drosophila and Xenopus laevis models. PLoS Genet. 2020;16(2):e1008590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7043793</ArticleId><ArticleId IdType="pubmed">32053595</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb J, Crawford ED, Peck D, et&#xa0;al. The Connectivity Map: using gene&#x2010;expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929&#x2010;1935.</Citation><ArticleIdList><ArticleId IdType="pubmed">17008526</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb J. The connectivity map: a new tool for biomedical research. Nat Rev Cancer. 2007;7(1):54&#x2010;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">17186018</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu XA, Rajpal DK. Applications of connectivity map in drug discovery and development. Drug Discov Today. 2012;17(23&#x2013;24):1289&#x2010;1298.</Citation><ArticleIdList><ArticleId IdType="pubmed">22889966</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Narayan R, Corsello SM, et&#xa0;al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017;171(6):1437&#x2010;1452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5990023</ArticleId><ArticleId IdType="pubmed">29195078</ArticleId></ArticleIdList></Reference><Reference><Citation>Kok JR, Palminha NM, Dos Santos SC, et&#xa0;al. DNA damage as a mechanism of neurodegeneration in ALS and a contributor to astrocyte toxicity. Cell Mol Life Sci. 2021;78(15):5707&#x2010;5729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8316199</ArticleId><ArticleId IdType="pubmed">34173837</ArticleId></ArticleIdList></Reference><Reference><Citation>Butti Z, Patten SA. RNA dysregulation in amyotrophic lateral sclerosis. Front Genet. 2019;9:712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6349704</ArticleId><ArticleId IdType="pubmed">30723494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan S, Bowser R. Alterations in G1 to S phase cell&#x2010;cycle regulators during amyotrophic lateral sclerosis. Am J Pathol. 2003;162(3):823&#x2010;835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868100</ArticleId><ArticleId IdType="pubmed">12598317</ArticleId></ArticleIdList></Reference><Reference><Citation>Kankel MW, Sen A, Lu L, et&#xa0;al. Amyotrophic lateral sclerosis modifiers in drosophila reveal the phospholipase d pathway as a potential therapeutic target. Genetics. 2020;215(3):747&#x2010;766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7337071</ArticleId><ArticleId IdType="pubmed">32345615</ArticleId></ArticleIdList></Reference><Reference><Citation>Azpurua J, El&#x2010;Karim EG, Tranquille M, Dubnau J. A behavioral screen for mediators of age&#x2010;dependent TDP&#x2010;43 neurodegeneration identifies SF2/SRSF1 among a group of potent suppressors in both neurons and glia. PLoS Genet. 2021;17(11):e1009882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8584670</ArticleId><ArticleId IdType="pubmed">34723963</ArticleId></ArticleIdList></Reference><Reference><Citation>Haarhuis JHI, van der Weide RH, Blomen VA, et&#xa0;al. A mediator&#x2010;cohesin axis controls heterochromatin domain formation. Nat Commun. 2022;13(1):1&#x2010;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8826356</ArticleId><ArticleId IdType="pubmed">35136067</ArticleId></ArticleIdList></Reference><Reference><Citation>Briese M, Saal&#x2010;Bauernschubert L, L&#xfc;ningschr&#xf6;r P, et&#xa0;al. Loss of Tdp&#x2010;43 disrupts the axonal transcriptome of motoneurons accompanied by impaired axonal translation and mitochondria function. Acta Neuropathol Commun. 2020;8(1):1&#x2010;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7379803</ArticleId><ArticleId IdType="pubmed">32709255</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyuncu S, Saez I, Lee HJ, et&#xa0;al. The ubiquitin ligase UBR5 suppresses proteostasis collapse in pluripotent stem cells from Huntington's disease patients. Nat Commun. 2018;9(1):1&#x2010;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6056416</ArticleId><ArticleId IdType="pubmed">30038412</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D&#x2010;H, Latimer C, Yagi M, et&#xa0;al. Heterozygous STUB1 missense variants cause ataxia, cognitive decline, and STUB1 mislocalization. Neurol Genet. 2020;6(2):1&#x2010;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7073456</ArticleId><ArticleId IdType="pubmed">32211513</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo CJJ, Simmons Z, De Vivo DC, Darras BT. Ethical perspectives on treatment options with spinal muscular atrophy patients. Ann. Neurol. 2022;91(3):305&#x2010;316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9305104</ArticleId><ArticleId IdType="pubmed">34981567</ArticleId></ArticleIdList></Reference><Reference><Citation>Nam SM, Choi JH, Choi S&#x2010;H, et&#xa0;al. Ginseng gintonin alleviates neurological symptoms in the G93A&#x2010;SOD1 transgenic mouse model of amyotrophic lateral sclerosis through lysophosphatidic acid 1 receptor. J Ginseng Res. 2021;45(3):390&#x2010;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8134849</ArticleId><ArticleId IdType="pubmed">34025132</ArticleId></ArticleIdList></Reference><Reference><Citation>Briones MRS, Snyder AM, Ferreira RC, Neely EB, Connor JR, Broach JR. A possible role for platelet&#x2010;activating factor receptor in amyotrophic lateral sclerosis treatment. Front Neurol. 2018;9:39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5810282</ArticleId><ArticleId IdType="pubmed">29472887</ArticleId></ArticleIdList></Reference><Reference><Citation>Monroy A, Lithgow GJ, Alavez S. Curcumin and neurodegenerative diseases. Biofactors. 2013;39(1):122&#x2010;132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3578106</ArticleId><ArticleId IdType="pubmed">23303664</ArticleId></ArticleIdList></Reference><Reference><Citation>Okano H, Yasuda D, Fujimori K, Morimoto S, Takahashi S. Ropinirole, a new ALS drug candidate developed using iPSCs. Trends Pharmacol Sci. 2020;41(2):99&#x2010;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">31926602</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Shefner JM, Schoenfeld DA, et&#xa0;al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol. 2006;60(1):22&#x2010;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">16802291</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Titus S, Kearney M, et&#xa0;al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi&#x2010;stage, randomised, double&#x2010;blind, placebo&#x2010;controlled trial. Lancet Neurol. 2014;13(11):1083&#x2010;1091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4216315</ArticleId><ArticleId IdType="pubmed">25297012</ArticleId></ArticleIdList></Reference><Reference><Citation>Laferri&#xe8;re F, Maniecka Z, P&#xe9;rez&#x2010;Berlanga M, et&#xa0;al. TDP&#x2010;43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates. Nat Neurosci. 2019;22(1):65&#x2010;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">30559480</ArticleId></ArticleIdList></Reference><Reference><Citation>Iridoy MO, Zubiri I, Zelaya MV, et&#xa0;al. Neuroanatomical quantitative proteomics reveals common pathogenic biological routes between amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Int J Mol Sci. 2018;20(1):4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6337647</ArticleId><ArticleId IdType="pubmed">30577465</ArticleId></ArticleIdList></Reference><Reference><Citation>Gozal YM, Dammer EB, Duong DM, et&#xa0;al. Proteomic analysis of hippocampal dentate granule cells in frontotemporal lobar degeneration: application of laser capture technology. Front Neurol. 2011;2:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3085134</ArticleId><ArticleId IdType="pubmed">21577247</ArticleId></ArticleIdList></Reference><Reference><Citation>Umoh ME, Dammer EB, Dai J, et&#xa0;al. A proteomic network approach across the ALS&#x2010;FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO mol Med. 2018;10(1):48&#x2010;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5760858</ArticleId><ArticleId IdType="pubmed">29191947</ArticleId></ArticleIdList></Reference><Reference><Citation>Pun FW, Liu BHM, Long X, et&#xa0;al. Identification of therapeutic targets for amyotrophic lateral sclerosis using PandaOmics&#x2013;an AI&#x2010;enabled biological target discovery platform. Front Aging Neurosci. 2022;14:914017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9273868</ArticleId><ArticleId IdType="pubmed">35837482</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>